文献速递治疗药物监测与药物基因组学特殊人群用药

CES1基因型对丹麦健康受试者哌甲酯药代动力学的影响

The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.
PubMed 文献 · Br J Clin Pharmacol · 2017-02-24

本研究在200名丹麦健康白种人中检测CES1基因型,并邀请44人参加开放前瞻性试验,接受单次口服10 mg哌甲酯。结果显示,携带CES1 143E等位基因者d-哌甲酯中位AUC显著高于对照组,4拷贝组也显著高于对照组和3拷贝组,提示CES1酶活性降低。

要点

  • CES1 143E等位基因携带者d-哌甲酯AUC显著升高,提示酶活性降低。
  • CES1 4拷贝组d-哌甲酯AUC显著高于对照组和3拷贝组。
  • 2拷贝与3拷贝组之间d-哌甲酯AUC无差异。

核心结论

  • CES1 143E等位基因导致d-哌甲酯AUC增加,提示CES1酶活性显著降低。
  • CES1纯合重复(4拷贝)受试者d-哌甲酯AUC也增加,可能反映影响酶活性的未发现突变。

研究设计与样本

  • 从200名健康丹麦白种人志愿者获取CES1基因型。
  • 基于基因型邀请44名受试者(19男25女)参加开放前瞻性试验,涉及六种预定义基因型。
  • 受试者单次口服10 mg哌甲酯,按计划时间点测定血浆哌甲酯及其主要代谢物浓度。

主要发现

  • 携带143E等位基因组d-哌甲酯中位AUC为53.3 ng ml-1 h-1(范围38.6-93.9),显著大于对照组21.4 ng ml-1 h-1(范围15.7-34.9)(P < 0.0001)。
  • 4拷贝组d-哌甲酯中位AUC为34.5 ng ml-1 h-1(范围21.3-62.8),显著大于对照组(P = 0.01)和3拷贝组23.8 ng ml-1 h-1(范围15.3-32.0,P = 0.03)。
  • 2拷贝组与3拷贝组之间d-哌甲酯AUC无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study investigated the influence of CES1 variations, including the single nucleotide polymorphism (SNP) rs71647871 (G143E) and variation in copy number, on the pharmacokinetics of a single oral dose of 10 mg methylphenidate. METHODS: CES1 genotype was obtained from 200 healthy Danish Caucasian volunteers. Based on the genotype, 44 (19 males and 25 females) were invited to participate in an open, prospective trial involving six predefined genotypes: three groups with two, three and four CES1 copies, respectively; a group of carriers of the CES1 143E allele; a group of individuals homozygous for CES1A1c (CES1VAR); and a group having three CES1 copies, in which the duplication, CES1A2, had increased transcriptional activity. Plasma concentrations of methylphenidate and its primary metabolites were determined at scheduled time points. RESULTS: Median AUC of d-methylphenidate was significantly larger in the group carrying the 143E allele (53.3 ng ml-1 h-1 , range 38.6-93.9) than in the control group (21.4 ng ml-1 h-1 , range 15.7-34.9) (P < 0.0001). Median AUC of d-methylphenidate was significantly larger in the group with four CES1 copies (34.5 ng ml-1 h-1 , range 21.3-62.8) than in the control group (P = 0.01) and the group with three CES1 copies (23.8 ng ml-1 h-1 , range 15.3-32.0, P = 0.03). There was no difference between the groups with two and three copies of CES1. CONCLUSIONS: The 143E allele resulted in an increased AUC, suggesting a significantly decreased CES1 enzyme activity. Surprisingly, this was also the case in subjects with homozygous duplication of CES1, perhaps reflecting an undiscovered mutation affecting the activity of the enzyme.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Stage C, Jürgens G, Guski LS, et al. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharmacol. 2017. PMID: 28087982. doi:10.1111/bcp.13237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。